TTF-1 Expression and Efficacy of Platinum and Pemetrexed Plus Pembrolizumab in Advanced Lung Adenocarcinoma
Platinum and pemetrexed combined with pembrolizumab remains an effective first-line treatment option for lung adenocarcinoma, regardless of <i>TTF-1</i> expression.
Authors
- Ninso Matsunaga
- Yasuhito Fujisaka (ORCID: https://orcid.org/0000-0002-9175-3627)
- Yosuke Shimazu (ORCID: https://orcid.org/0000-0002-7696-7811)
- SHO MITSUYA
- Shigeru Kawabata (ORCID: https://orcid.org/0000-0003-3948-4500)
- Tomoya Funamoto
- Takahiko Nakamura (ORCID: https://orcid.org/0000-0003-3604-6927)
- Masahiro Arai (ORCID: https://orcid.org/0000-0002-6312-6319)
- Yosuke Tamura (ORCID: https://orcid.org/0009-0000-0513-2860)
- Soichiro Ikeda
- Kenjiro Tsuruoka
- KAZUHIRO TAKEZAKI
- HIDEAKI KAWAGUCHI
- HIROYUKI TSUJI
- AKIRA YURA
- SHOICHI ISHIKAWA
- YUKI ASAI
- RYUTARO YAMAGUCHI
Institutions
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-12-30
- DOI
- https://doi.org/10.21873/anticanres.17958
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00